StemGen is a clinical state biotech company developing Innovative differentiation biotherapies for cancer.

hrBMP4 gets the Orphan Drug designation by EMA
for the treatment of glioma.
Year 2014

Rare tumors

Glioblastoma Multiforma is the most common and aggressive malignant primary brain tumour, considered incurable.

Current standard of care  is of limited benefit and prognosis is poor.

Our solution: differentiation therapy

A therapy that turns cancer stem cells into “normal” mature brain cells.